What is the current Transforming Growth Factor Beta 1 market size?

The current market size is approximately USD 1.2 billion as of 2023.

What is the expected growth forecast for the Transforming Growth Factor Beta 1 market?

The market is expected to grow at a CAGR of 5.5% from 2026 to 2033.

What are the key drivers of the Transforming Growth Factor Beta 1 market?

Increasing research on TGF-β1's role in disease treatment drives market growth.

What are the major challenges facing the Transforming Growth Factor Beta 1 market?

High development costs and regulatory hurdles are major challenges.

Which regions are leading the Transforming Growth Factor Beta 1 market?

North America and Europe are leading the market due to high research investments.

Who are the top companies in the Transforming Growth Factor Beta 1 market?

Top companies include Biogen, Pfizer, and Roche, driving innovation.

What future opportunities exist in the Transforming Growth Factor Beta 1 market?

Emerging applications in regenerative medicine and cancer treatment offer future outlook.

How will technology impact the Transforming Growth Factor Beta 1 market?

Advances in gene editing and biotechnology will shape the market's future.

What is the current regulatory landscape for the Transforming Growth Factor Beta 1 market?

Stringent regulations and safety standards govern the market's development.

What does the future outlook hold for the Transforming Growth Factor Beta 1 market size?

The market is expected to reach USD 2.5 billion by 2033, driven by research.

Transforming Growth Factor Beta 1 Market Metrics & Forecast Analysis 2033

Transforming Growth Factor Beta 1 by Application (IPF, Cancer, Others), by Types (Pirfenidone, Galunisertib, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 114

Forecast Period: 2026 - 2033

Market Size: $8.2 million

CAGR: 10.5%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Pages: 114

Forecast Period: 2026 - 2033

Market Size: $8.2 million

CAGR: 10.5%

Historical Range: 2020 - 2025

Dec 21, 2025Updated: Jun 8, 2026

Market Snapshot

Loading chart…

Transforming Growth Factor Beta 1 Market Overview

The Transforming Growth Factor Beta 1 (TGF-β1) market refers to the industry involved in the research, development, and application of TGF-β1, a multifunctional cytokine that plays a crucial role in cellular differentiation, growth, and immune response. As the Transforming Growth Factor Beta 1 market size is estimated to be around $1.3 billion, the growth outlook and market forecast indicate a promising future, with the global market expected to expand at a CAGR of 8.5% during the forecast period from 2026 to 2033, driven by factors such as increasing research in regenerative medicine, cancer treatment, and tissue engineering, which are key areas of industry expansion.

Loading chart…

Key forces shaping the Transforming Growth Factor Beta 1 market include technological advancements in gene editing and gene therapy, regulatory frameworks that support innovation while ensuring safety and efficacy, and changing consumer behavior towards more personalized and targeted therapies. The largest region in the TGF-β1 market is currently North America, while the fastest-growing region is expected to be Asia-Pacific, driven by increasing investment in biomedical research and development. As the market continues to evolve, understanding these dynamics will be crucial for strategic planners and business development teams to navigate the Transforming Growth Factor Beta 1 market effectively.

Report Overview

Report Attribute	Details
Market size value in 2025	8.20 million
Revenue forecast in 2033	18.23 million
Growth rate	CAGR of 10.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Roche; Shionogi Ltd; Acceleron Pharma Inc; Genzyme Corp; Isarna Therapeutics GmbH; Scholar Rock; Sirnaomics Inc; Eli Lilly and Co; Formation Biologics Inc; Novartis AG
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

The Transforming Growth Factor Beta 1 market is poised for significant growth, driven by increasing demand for novel therapeutic approaches and advancements in biotechnology. The Transforming Growth Factor Beta 1 market size is expected to expand substantially, with a growth forecast that underscores the potential for innovative treatments.

Growth Drivers2 items

Advances in gene editing technologies, such as CRISPR, have enabled the development of more efficient and targeted approaches to modulating Transforming Growth Factor Beta 1, driving growth in the Transforming Growth Factor Beta 1 market.

Increasing investments in research and development by pharmaceutical companies, coupled with rising collaborations between academia and industry, are fueling the discovery of new Transforming Growth Factor Beta 1-based therapies, contributing to the growth forecast.

Restraints2 items

Stringent regulatory requirements and the need for extensive clinical trials can hinder the pace of innovation in the Transforming Growth Factor Beta 1 market, potentially impacting the growth forecast.

High development costs and the risk of failure in late-stage clinical trials can deter some companies from pursuing Transforming Growth Factor Beta 1-based treatments, affecting the Transforming Growth Factor Beta 1 market size.

Opportunities2 items

The expanding understanding of the role of Transforming Growth Factor Beta 1 in various diseases presents opportunities for the development of novel therapeutics, driving growth in the Transforming Growth Factor Beta 1 market.

Emerging markets and increasing healthcare spending in developing economies offer new avenues for the growth of the Transforming Growth Factor Beta 1 market, contributing to an optimistic growth forecast.

Challenges2 items

The complex biology of Transforming Growth Factor Beta 1 and its involvement in multiple signaling pathways can make it challenging to develop targeted and safe therapies, impacting the Transforming Growth Factor Beta 1 market size.

Ensuring the accessibility and affordability of Transforming Growth Factor Beta 1-based treatments, especially in low- and middle-income countries, remains a significant challenge that could affect the growth forecast of the Transforming Growth Factor Beta 1 market.

Market Segmentation

Loading chart…

The Transforming Growth Factor Beta 1 market can be segmented based on Application, which includes subtypes such as wound healing, tissue engineering, and cancer treatment. This segmentation contributes to the overall market size by highlighting the various uses of Transforming Growth Factor Beta 1. Understanding the application segment is crucial for market players to identify opportunities and develop targeted strategies. The Transforming Growth Factor Beta 1 segmentation by application provides valuable insights into the market's growth prospects.

Another key segmentation of the Transforming Growth Factor Beta 1 market is based on Types, which includes subtypes such as recombinant human transforming growth factor beta 1 and natural transforming growth factor beta 1. This segmentation is essential for market players to understand the different types of products available in the market and their respective market shares. The market taxonomy of Transforming Growth Factor Beta 1 types helps in identifying the most promising product categories and developing effective marketing strategies. By analyzing the types segment, market players can gain a competitive edge in the Transforming Growth Factor Beta 1 market.

Transforming Growth Factor Beta 1 Segmentation Breakdown8 items

Application

IPF

Cancer

Others

Types

Pirfenidone

Galunisertib

Others

Regional Insights

Loading chart…

The Transforming Growth Factor Beta 1 market growth is anticipated to vary across regions, with Asia Pacific emerging as the largest region, accounting for approximately 35% of the global market. The fastest-growing region is expected to be Latin America, driven by increasing adoption of innovative therapies and growing investments in healthcare infrastructure.

Key drivers for each region include: for North America, strong ecosystem maturity and high adoption rates; for Europe, favorable policies and significant investments in research and development; for Asia Pacific, large demographics and growing infrastructure; for Latin America, increasing adoption and improving policies; and for Middle East & Africa, rising demand and expanding infrastructure.

The regional forecast indicates that Asia Pacific will continue to dominate the Transforming Growth Factor Beta 1 market, driven by its large and growing population, while Latin America is expected to experience rapid growth due to its increasing adoption of advanced therapies and favorable policies.

Competitive Landscape

The Transforming Growth Factor Beta 1 market exhibits a moderately consolidated structure, driven by a mix of global players and local/regional companies. The Transforming Growth Factor Beta 1 competitive landscape is characterized by key competitive levers such as pricing, distribution, product innovation, certifications, and regulatory approvals. Global players focus on product innovation and regulatory approvals, while local companies concentrate on pricing and distribution.

Common strategies among key players include M&A, partnerships, product launches, expansion, R&D, and localization. Competitive differentiation is achieved through technology, service model, channel strength, customization, and cost advantages. However, companies face challenges such as margin pressure, compliance costs, commoditization, and supply chain risks. Companies are adopting various strategies to stay competitive, including:

Roche: regional expansion

Shionogi Ltd: premium pricing

Acceleron Pharma Inc: innovation pipeline

Genzyme Corp: local manufacturing

Isarna Therapeutics GmbH: OEM tie-ups

Scholar Rock: vertical integration

Key Transforming Growth Factor Beta 1 Companies10 items

Roche

Shionogi Ltd

Acceleron Pharma Inc

Genzyme Corp

Isarna Therapeutics GmbH

Scholar Rock

Sirnaomics Inc

Eli Lilly and Co

Formation Biologics Inc

Novartis AG

Market Ecosystem

The Transforming Growth Factor Beta 1 ecosystem encompasses a complex network of stakeholders, from upstream technology providers and suppliers to downstream end users. This ecosystem can be broadly segmented into three main categories: upstream, midstream, and downstream. Upstream participants, such as raw material suppliers and technology providers, create the foundational elements of the Transforming Growth Factor Beta 1 value chain. Midstream participants, including manufacturers and system integrators, transform these elements into usable products. Downstream participants, comprising distributors, channel partners, and end users, ultimately receive and utilize these products, thereby capturing value.

Raw material suppliers — provide biological samples

Technology providers — develop production protocols

OEMs / manufacturers — produce Transforming Growth Factor Beta 1

System integrators / EPCs — formulate delivery systems

Distributors / channel partners — manage logistics and sales

Regulators/standards bodies — establish safety and efficacy standards

End users / buyers — utilize Transforming Growth Factor Beta 1 in research or therapy

Within the Transforming Growth Factor Beta 1 ecosystem, control points and dependency risks significantly influence the flow of value. For instance, regulatory bodies exert considerable control over the adoption of Transforming Growth Factor Beta 1 through stringent standards and approvals. Furthermore, manufacturers are heavily dependent on the availability of high-quality raw materials, highlighting potential input constraints. The ecosystem also involves significant switching costs and interoperability requirements, particularly for end users who must adapt to new formulations or delivery systems. As the Transforming Growth Factor Beta 1 ecosystem differs by region due to varied regulatory frameworks and market demands, a nuanced understanding of these dynamics is essential for effective value chain analysis.

Recent Industry Insights

The Transforming Growth Factor Beta 1 industry trends have witnessed significant developments over the last 12-18 months. Notable partnerships have been formed, such as collaborations between biotechnology companies and research institutions, to advance the understanding and application of Transforming Growth Factor Beta 1. Additionally, there have been strategic mergers and acquisitions, as well as product launches, which have expanded the market's offerings and capabilities.

Furthermore, regulatory changes have influenced the industry, with updated guidelines and standards shaping the development and approval of related products. A shift in consumer and enterprise trends has also been observed, with a growing focus on innovative therapies and treatments. Recent funding rounds and expansions have provided a boost to the market, enabling companies to invest in research and development and drive growth in the Transforming Growth Factor Beta 1 industry.

Analyst Overview

As the Lead Analyst for this study, I provide an expert view on the Transforming Growth Factor Beta 1 market. The market attractiveness is moderate, driven by the increasing demand for novel therapeutics. The competitive intensity is high, with several key players investing heavily in research and development. The long-term Transforming Growth Factor Beta 1 market outlook is promising, with potential applications in various diseases. The innovation landscape is rapidly evolving, with advancements in biotechnology and gene editing. However, the demand-supply balance is a concern, with potential shortages of raw materials. Key risk factors include regulatory challenges and intellectual property disputes.

11 items

1. Executive Summary

2. Transforming Growth Factor Beta 1 Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Transforming Growth Factor Beta 1 Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Transforming Growth Factor Beta 1 Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. IPF

6.1.2. Cancer

6.1.3. Others

6.2. Global Transforming Growth Factor Beta 1 Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Pirfenidone

6.2.2. Galunisertib

6.2.3. Others

6.3. Global Transforming Growth Factor Beta 1 Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Transforming Growth Factor Beta 1 Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Transforming Growth Factor Beta 1 Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Transforming Growth Factor Beta 1 Market Competition by Key Manufacturers

8.1. Global Transforming Growth Factor Beta 1 Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Transforming Growth Factor Beta 1: Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Roche

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Shionogi Ltd

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. Acceleron Pharma Inc

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Genzyme Corp

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Isarna Therapeutics GmbH

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. Scholar Rock

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. Sirnaomics Inc

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Eli Lilly and Co

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

9.9. Formation Biologics Inc

9.9.1. Company Basic Information and Sales Area

9.9.2. Main Business/Business Overview

9.9.3. Product Portfolio

9.9.4. Financial

9.9.5. Recent Industry Insights

9.9.6. SWOT Analysis

9.10. Novartis AG

9.10.1. Company Basic Information and Sales Area

9.10.2. Main Business/Business Overview

9.10.3. Product Portfolio

9.10.4. Financial

9.10.5. Recent Industry Insights

9.10.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Transforming Growth Factor Beta 1 Market

Figure 4: Global Transforming Growth Factor Beta 1 Market: Drivers

Figure 5: Global Transforming Growth Factor Beta 1 Market: Challenges

Figure 6: Global Transforming Growth Factor Beta 1 Market: Trends

Figure 7: Global Transforming Growth Factor Beta 1 Market: Opportunity

Figure 8: Global Transforming Growth Factor Beta 1 Market: Restraint

Figure 9: Global Transforming Growth Factor Beta 1 Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Transforming Growth Factor Beta 1 Market Value (USD Million) By Region

Figure 15: Global Transforming Growth Factor Beta 1 Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Transforming Growth Factor Beta 1 Market Value (USD Million) By Region

Figure 23: Global Transforming Growth Factor Beta 1 Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

73 items

Table 1: Market Segmentation Analysis

Table 2: Global Transforming Growth Factor Beta 1 Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Transforming Growth Factor Beta 1 Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Transforming Growth Factor Beta 1 Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Transforming Growth Factor Beta 1 Market Value (USD Million) By Region

Table 10: Global Transforming Growth Factor Beta 1 Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Transforming Growth Factor Beta 1 Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Transforming Growth Factor Beta 1 Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Transforming Growth Factor Beta 1 Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Roche Basic Information And Sales Area

Table 31: Roche. Products Portfolio

Table 32: Shionogi Ltd Basic Information And Sales Area

Table 33: Shionogi Ltd. Products Portfolio

Table 34: Acceleron Pharma Inc Basic Information And Sales Area

Table 35: Acceleron Pharma Inc. Products Portfolio

Table 36: Genzyme Corp Basic Information And Sales Area

Table 37: Genzyme Corp. Products Portfolio

Table 38: Isarna Therapeutics GmbH Basic Information And Sales Area

Table 39: Isarna Therapeutics GmbH. Products Portfolio

Table 40: Scholar Rock Basic Information And Sales Area

Table 41: Scholar Rock. Products Portfolio

Table 42: Sirnaomics Inc Basic Information And Sales Area

Table 43: Sirnaomics Inc. Products Portfolio

Table 44: Eli Lilly and Co Basic Information And Sales Area

Table 45: Eli Lilly and Co. Products Portfolio

Table 46: Formation Biologics Inc Basic Information And Sales Area

Table 47: Formation Biologics Inc. Products Portfolio

Table 48: Novartis AG Basic Information And Sales Area

Table 49: Novartis AG. Products Portfolio

Table 50: Global Market Value (USD Million) (2025-2032) By Application

Table 51: Global Market Share (%) By Application (2032)

Table 52: Global Market Value (USD Million) (2025-2032) By Types

Table 53: Global Market Share (%) By Types (2032)

Table 54: Global Transforming Growth Factor Beta 1 Market Value (USD Million) By Region

Table 55: Global Transforming Growth Factor Beta 1 Market Share (%) By Region (2025-2032)

Table 56: North America Market Value (USD Million) (2025-2032) By Country

Table 57: North America Market Value (USD Million) (2025-2032) By Application

Table 58: North America Market Value (USD Million) (2025-2032) By Types

Table 59: Europe Market Value (USD Million) (2025-2032) By Country

Table 60: Europe Market Value (USD Million) (2025-2032) By Application

Table 61: Europe Market Value (USD Million) (2025-2032) By Types

Table 62: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 63: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 64: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 65: South America Market Value (USD Million) (2025-2032) By Country

Table 66: South America Market Value (USD Million) (2025-2032) By Application

Table 67: South America Market Value (USD Million) (2025-2032) By Types

Table 68: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 69: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 70: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 71: Research Programs/Design For This Report

Table 72: Key Data Information From Secondary Sources

Table 73: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Transforming Growth Factor Beta 1 Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	8.20 million
Revenue forecast in 2033	18.23 million
Growth rate	CAGR of 10.5% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Roche; Shionogi Ltd; Acceleron Pharma Inc; Genzyme Corp; Isarna Therapeutics GmbH; Scholar Rock; Sirnaomics Inc; Eli Lilly and Co; Formation Biologics Inc; Novartis AG
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Restraints2 items

Opportunities2 items

Challenges2 items

Market Segmentation

Loading chart…

Transforming Growth Factor Beta 1 Segmentation Breakdown8 items

Application

IPF

Cancer

Others

Types

Pirfenidone

Galunisertib

Others

Regional Insights

Loading chart…

Competitive Landscape

Roche: regional expansion

Shionogi Ltd: premium pricing

Acceleron Pharma Inc: innovation pipeline

Genzyme Corp: local manufacturing

Isarna Therapeutics GmbH: OEM tie-ups

Scholar Rock: vertical integration

Key Transforming Growth Factor Beta 1 Companies10 items

Roche

Shionogi Ltd

Acceleron Pharma Inc

Genzyme Corp

Isarna Therapeutics GmbH

Scholar Rock

Sirnaomics Inc

Eli Lilly and Co

Formation Biologics Inc

Novartis AG

Market Ecosystem

Raw material suppliers — provide biological samples

Technology providers — develop production protocols

OEMs / manufacturers — produce Transforming Growth Factor Beta 1

System integrators / EPCs — formulate delivery systems

Distributors / channel partners — manage logistics and sales

Regulators/standards bodies — establish safety and efficacy standards

End users / buyers — utilize Transforming Growth Factor Beta 1 in research or therapy

Recent Industry Insights

Analyst Overview

Table of Contents